Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133960 | 0.93 | ADORA2A (0.47) | ADORA2AADORA1HIF1ATLR7 | |
| SCHEMBL6135229 | 0.88 | APP (0.43) | ADORA2AADORA1ADORA2BADORA3SMN1; SMN2 | |
| SCHEMBL6134701 | 0.81 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BHIF1ATLR7 | |
| SCHEMBL6133268 | 0.81 | CALCA (0.41) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6133703 | 0.81 | GHSR (0.41) | ADORA2AADORA1ADORA3 | |
| SCHEMBL6133364 | 0.80 | ADORA2A (0.43) | ADORA2AADORA1MAPK14MAPK13MAPK12 | |
| SCHEMBL6133911 | 0.79 | NLRP3 (0.45) | ADORA2AADORA1 | |
| SCHEMBL5147963 | 0.78 | HIF1A (0.43) | ADORA2AADORA1HIF1AKCNA5 | |
| SCHEMBL6133629 | 0.78 | ADORA2A (0.37) | ADORA2AADORA1ADORA2BHIF1A | |
| SCHEMBL6134404 | 0.78 | ADORA2A (0.45) | ADORA2AADORA1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.